Indegene Ltd

Mr. Mark Francis Dzialga has resigned as a Non-Executive Non-Independent Director of Indegene Ltd, effective October 29, 2026. The resignation is a consequence of Brighton Park Capital and its affiliated investment vehicles selling their entire shareholding in the company. Mr. Dzialga will also cease to be a member of the Nomination and Remuneration Committee and the Investment Committee. He has confirmed that his resignation is not due to any disagreement with the company on matters of operations, corporate governance, or otherwise.

Indegene Ltd held its Digital Summit 2026 in Philadelphia, focusing on operationalizing AI in the life sciences sector. The event attracted over 120 senior pharma leaders, including 50% decision-makers and 70% Director+ level executives, with increased participation from both large and emerging biopharma companies compared to 2025. Key themes included AI operating models, customer engagement, enterprise transformation, and the future of work. Indegene's AI and platform capabilities were highlighted as a strong theme, with 8 sessions dedicated to exploring AI's impact and performance, showcasing the company's expertise in AI-native pharma enablement. The summit also saw participation from industry leaders, AI innovators, policymakers, and analysts, expanding the conversation beyond traditional pharma.

Indegene Ltd has announced that its Board of Directors will convene on October 29, 2026. The primary agenda for this meeting is to consider and approve the unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026. The meeting will also address the allotment of shares under the RSU Scheme 2020 and ESOP Scheme 2020. Concurrently, the trading window for the company's securities will remain closed from October 1, 2026, until 48 hours after the declaration of these financial results.

Indegene Ltd has announced the closure of its trading window for dealing in the company's securities. This closure is effective from October 1, 2026, and is in connection with the finalization and approval of its standalone and consolidated financial results for the quarter and half-year ended September 30, 2026. The trading window will reopen 48 hours after the financial results are declared and disseminated to the stock exchanges. All designated persons and insiders are advised not to trade in the company's equity shares during this period.

Indegene hosted its eighth Digital Summit, themed 'From Promise to Performance: Operationalizing AI for Enterprise Outcomes.' The event gathered over 200 life sciences leaders to discuss translating AI investments into measurable business impact. Discussions focused on adapting operating models, data, governance, and talent for AI integration. Key themes included AI's role in strategic decision-making, product launches, customer experience, and accelerating drug discovery. The summit also featured the VITAL Awards, recognizing leaders in organizational and market impact.

Indegene Limited announced the effective merger of its indirect wholly owned subsidiaries in Germany, Indegene Healthcare Germany GmbH and Trilogy Writing & Consulting GmbH, on September 9, 2026. The merger was registered with the Commercial Register of Frankfurt am Main. Following the merger, Indegene Healthcare Germany GmbH ceased to exist, and Trilogy Writing & Consulting GmbH became the surviving entity, subsequently renamed Indegene Healthcare Germany GmbH. This internal restructuring is not expected to materially impact Indegene Limited's business operations, shareholding, or financial position. The projected revenue for the surviving entity for FY 2026-27 is estimated at Euro 20,100,000.

Indegene Limited announced a material development in the class-action lawsuit against its wholly-owned subsidiary, Indegene, Inc., concerning the Telephone Consumer Protection Act (TCPA), 1991. On August 27, 2026, the U.S. District Court, District of New Jersey, issued an order preliminarily approving the proposed settlement. The court also approved the notice process, appointed Analytics as the Settlement Administrator, and scheduled the final approval hearing for January 12, 2027. The settlement framework includes a maximum settlement fund of approximately USD 4.72 million, with payments of USD 250 per eligible approved claim on a claims-made basis. This preliminary approval is subject to the completion of the notice and claims process and final court approval.

Indegene Ltd announced an update on a material litigation involving its wholly-owned subsidiary, Indegene, Inc. The class-action lawsuit, filed under the U.S. Telephone Consumer Protection Act, 1991 (TCPA), alleged violations concerning certain fax communications in February 2020. Following class certification and denial of appeal, parties entered mediation and negotiated settlement terms. Negotiations on the definitive settlement agreement are substantially concluded, with the company authorizing its execution. The settlement, subject to final execution and court approval, does not admit liability. The maximum settlement fund is approximately USD 4.72 million, calculated at USD 250 per eligible fax/claim. The actual payout depends on the number of valid claims submitted.

Indegene Limited conducted its 28th Annual General Meeting (AGM) on August 13, 2026, via video conferencing. The meeting was held in compliance with SEBI regulations, and the transcript is now available on the company's website. Key management personnel, including Chairman Manish Gupta, Executive Director Dr. Sanjay Suresh Parikh, CFO Suhas Prabhu, and Company Secretary Srishti Ramesh Kaushik, were present. The AGM focused on shareholder engagement and company governance, with provisions for electronic voting through NSDL.

Indegene Ltd announced the appointment of Ms. Jill Mary De Simone as an Independent Director, approved by shareholders at the 28th Annual General Meeting held on August 13, 2026. Ms. De Simone's term is for three years, effective January 22, 2026, to January 21, 2029. She brings extensive experience from leadership roles in biopharmaceutical companies like Merck, Teva, and Bristol Myers Squibb, with expertise in oncology, HIV, and general medicine. Currently, she advises life sciences companies and serves on boards, focusing on commercialization and AI in healthcare. She is not related to any existing director and is not debarred from holding a directorship.